This systematic review assesses cardiovascular adverse events in cancer patients undergoing CAR-T, BiTEs, and TILs, indicating the need for careful monitoring.
Key Points
The meta-analysis includes 107 studies assessing cardiovascular adverse events in CAR-T, BiTEs, and TILs therapies.
Cytokine release syndrome was highest in CAR-T therapy at 85.7%, contrasting sharply with TILs and BiTEs.
Heart failure incidence was low at 1.1% within 30 days, with no differences across therapy types.
Arrhythmias were reported at 4.6% in the first 30 days, showing a need for ongoing monitoring in observational studies.